Clonal Cytopenia of Undetermined Significance Clinical Trial
Official title:
A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04102423 -
CHIP/CCUS Natural History Protocol
|
||
| Recruiting |
NCT03418038 -
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02958462 -
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
|
N/A | |
| Recruiting |
NCT05641831 -
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
|
Phase 2 | |
| Recruiting |
NCT05483010 -
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04902833 -
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
|
||
| Not yet recruiting |
NCT06240754 -
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
|
Phase 2 | |
| Not yet recruiting |
NCT06063486 -
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
|
Phase 2 | |
| Recruiting |
NCT05030441 -
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
|
Phase 2 |